Maintaining therapeutic activity in the operating room: Compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids

Ryan Burnett, Carlos E. Ibañez, Pär L. Pettersson, Ching I. Chen, Shraddha Parab, Tiffany Huang, Joan Robbins, Krystof Bankiewicz, Manish Aghi, Christopher Logg, Noriyuki Kasahara, Dan Pertschuk, Harry E. Gruber, Douglas J. Jolly

Research output: Contribution to journalArticle

Abstract

Toca 511 is a novel retroviral replicating vector, encoding a modified yeast cytosine deaminase, administered to recurrent high grade glioma patients in Phase 1 trials by stereotactic, transcranial injection into the tumor or into the walls of the resection cavity. A key issue, with little published data, is vector biocompatibility with agents likely to be encountered in a neurosurgical setting. We tested biocompatibility of Toca 511 with: delivery devices; MRI contrast agents, including ProHance supporting coinjection for real time MRI-guided intratumoral delivery; hemostatic agents; biofluids (blood and cerebrospinal fluid); potential adjuvants; and a needleless vial adapter that reduces risk of accidental needle sticks. Toca 511 is stable upon thawing at ambient temperature for at least 6 hours, allowing sufficient time for administration, and its viability is not reduced in the presence of: stainless steel and silica-based delivery devices; the potential MRI contrast agent, Feraheme; ProHance at several concentrations; the hemostatic agent SURGIFOAM; blood; cerebrospinal fluid; and the needleless vial adapter. Toca 511 is not compatible with the hemostatic agent SURGICEL or with extended exposures to titanium-based biopsy needles.

Original languageEnglish (US)
Article number14024
Number of pages1
JournalMolecular Therapy - Methods and Clinical Development
Volume1
DOIs
StatePublished - Jan 8 2014

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Fingerprint Dive into the research topics of 'Maintaining therapeutic activity in the operating room: Compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids'. Together they form a unique fingerprint.

  • Cite this

    Burnett, R., Ibañez, C. E., Pettersson, P. L., Chen, C. I., Parab, S., Huang, T., Robbins, J., Bankiewicz, K., Aghi, M., Logg, C., Kasahara, N., Pertschuk, D., Gruber, H. E., & Jolly, D. J. (2014). Maintaining therapeutic activity in the operating room: Compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids. Molecular Therapy - Methods and Clinical Development, 1, [14024]. https://doi.org/10.1038/mtm.2014.24